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INTRODUCTION BACKGROUND:
In the last decade, considerable progress has been made in understanding the complex regulatory networks that control immune responses. Regulating the extent, quality and duration of immune responses is critical for balancing protective immunity and tissue injury. Costimulatory (CD28, ICOS) and inhibitory (CTLA4, PD-1) molecules of the CD28 receptor family provide critical secondary signals regulating this balance, and recent work has uncovered critical roles for CTLA4 and PD-1 in restraining immune responses in chronic viral infection and malignancy. We recently cloned B-and T-lymphocyte attenuator (BTLA), the third inhibitory receptor of the CD28 family expressed on lymphocytes. Using BTLA-deficient mice and monoclonal antibodies specific for BTLA that we generated, we have studied several in vivo models of infection and autoimmunity, showing the importance of BTLA in regulating immune responses. Several lines of evidence suggest that inhibitory molecules such as CTLA-4 and PD-1 limit cancer immunosurveillance.
OBJECTIVE/HYPOTHESIS:
The hypothesis of this application is that BTLA contributes to the inhibition of breast cancer immunosurveillance, and selective targeting of the BTLA-LIGHT-HVEM costimulatory system can enhance breast cancer immunity.
SPECIFIC AIMS:
(1) Define the role of BTLA in breast cancer immunosurveillance. 
PROGRESS:
The award was in the format of a Synergistic Idea Award to William E. Gillanders, M.D., a breast cancer surgeon, and Kenneth Murphy, M.D., Ph.D., a basic immunologist. The current report represents a final report for the entire period including the no-cost extension period in which Dr. Gillanders continued the studies.
The overall aim was to evaluate the role of BTLA in breast cancer immunosurveillance, and develop novel therapeutics targeting the BTLA-LIGHT-HVEM costimulatory system. During the course of the study period, we have made a number of important observations that provide important insights into the role of BTLA in breast cancer immunosurveillance, into the basic biology of BTLA, and into mechanisms of antigen presentation following DNA vaccination: (1) We performed studies in human breast cancer specimens demonstrating that expression of BTLA in human breast cancers of various histologic types is restricted to only 1-3% of CD8 T cells in primary tumors and tumor-draining lymph nodes (Please see Appendix 1) . These studies suggest that BTLA may only have a limited role in breast cancer immunosurveillance, the key question addressed in Specific Aim 1. (2) Various HVEM mutants were generated that ablate binding of BTLA but preserve binding of LIGHT. These constructs were constructed in an attempt to dissociate T cell costimulation and inhibition in the BTLA-LIGHT-HVEM costimulatory system. However, we observed that wildtype HVEM, but not mutant HVEM, Page 4 of 29 is an effective molecular adjuvant in the context of DNA vaccination. This surprising finding was not predicted by our original hypothesis (Please see Appendix 3, 4) . Of note, this surprising finding provided key insights that lead directly to important studies of BTLA biology in graft versus host disease, and the mechanisms of antigen presentation following DNA vaccination. Specifically, we found that (3) In a murine graft-versus-host disease (GVHD) model anti-BTLA therapy permanently prevented GVHD through blockade of alloreactive donor T cells, and (4) BTLA is highly expressed on a subset of dendritic cells uniquely qualified for cross-presentation of antigen and generation of effective T cell immunity. We are particularly excited by the latter finding and were recently successful in securing funds to continue these studies.
BODY Specific Aim 1:
To assess the role of BTLA in breast cancer immune surveillance we determined expression of BTLA in peripheral blood, lymph nodes, and tumor tissue in human breast cancer patients. Both flow cytometry and immunohistochemistry was performed. Co-staining for CD8 showed very few (<5%) of CD8 T cells express BTLA. However, BTLA is highly expressed on a subset of dendritic cells involved in cross presentation. Please see Appendix #1 for details.
Specific Aims 2A, 2B: Progress in the studies outlined in these Aims were hampered by the fact that our BALB/c-neuT breeding colony had to be re-established, causing a significant delay in establishing a BALB/cneuT/BTLA -/-strain. Once we successfully expanded our colony of BALB/c-neuT mice, breeding of BALB/cneuT mice to BTLA-deficient mice was initiated. No spontaneous tumors from BALB/c-neuT mice have been evaluated as all animals of sufficient age and appropriate genetic background were used to cross with BTLAdeficient mice or for vaccination experiments outlined in 3C. Breeding BAL/c-neuT to BTLA-deficient mice proved very difficult. While we did generate F1 mice, backcrossing F1 to BTLA -/-mice appeared lethal. These studies will be continued using funds from other sources.
Specific Aims 3A, 3B: LIGHT signaling through HVEM results in CD28-independent T cell costimulation, dramatically enhancing antitumor and other cell-mediated immune responses, whereas BTLA signaling through HVEM induces inhibitory signals. We earlier reported the successful creation of three different HVEM mutants using site-directed mutagenesis: P17A, Y23A, and V36A with the goal to ablate binding of BTLA but preserve binding of LIGHT. The mutant constructs were initially expressed in CHO cells to assess binding of HVEM and BTLA. Subsequently, the mutant constructs were cloned into pcDNA3 vector for further functional validation. In vitro studies confirm that P17A successfully ablates BTLA interaction. Functional analysis In three independent experiments showed the surprising finding that administration of wildtype HVEM enhances the immune response to OVA cDNA, but the P17A mutant HVEM unexpectedly did not. Please see Appendices 3
and 4 for additional details.
Specific Aim 3C: Wildtype (wt) and mutant HVEM constructs were successfully cloned into the pcDNA3 plasmid DNA vector, and expression was confirmed. To assess their ability to enhance DNA vaccination, several vaccination protocols were developed based on the model antigen, ovalbumin (OVA) . Surprisingly, our data suggest that wildtype, but not mutant HVEM, is an effective molecular adjuvant in the context of DNA vaccination. In addition, we have validated a clinically relevant breast cancer vaccine model in our laboratory to test the HVEM constructs. This model system is based on the BALB/c-neuT genetically engineered murine model of breast cancer. BALB/c-neuT mice express the transforming rat oncogene HER2/neu under the mouse mammary tumor virus (MMTV) promoter. These mice spontaneously develop breast cancer with a welldefined progression from dysplasia, to in situ carcinoma, to overt invasive carcinoma similar to human disease. Of relevance to the current proposal, we have found that HVEM is not involved in the mechanisms of the beneficial effects of BTLA-directed therapy. During homeostatic expansion, HVEM is not engaged to limit the expansion of effector T cells after BMT. This observation may alter our future focus to concentrate on BTLA rather than HVEM manipulations in considering ways to augment anti-tumor vaccinations. Please see Appendix #6 for manuscript published in Journal of Experimental Medicine.
Additional Studies II:
While our studies on BTLA expression in CD8 T cells infiltrating human breast tumors yielded disappointing results, we were surprised to detect substantial BTLA expression in dendritic cells.
Further study through flow cytometry showed that expression of BTLA is most prominent in a subset of dendritic cells expressing CD8α/CD103 in mice and Clec9A in humans. Recent studies by the Murphy and Gillanders laboratories have characterized this subset of dendritic cells as the cells uniquely capable of crosspresentation and cross-dressing, and priming of CD8 T cells after vaccination. Mice deficient in this subset of dendritic cells failed to stimulate naïve CD8 T cells following DNA or cellular vaccination. Please see Appendix #7 for manuscript published in PNAS and Appendix #8 for additional data.
Problem Areas:
We encountered an unforeseen problem when the postdoctoral fellow recruited to work on this project left unexpectedly due to family health issues. This individual ultimately resigned the position, and this unexpected departure ultimately resulted in having to re-establish the BALB/c-neuT and related mouse colonies. We successfully recruited another postdoctoral fellow to fill the position. This individual has a strong background in tumor immunology and vaccine development. In addition, towards the end of year two we recruited a second postdoctoral fellow to work on this project. This individual has obtained a postdoctoral fellowship award from the Swiss National Foundation, and the main focus of her proposed studies was the studies described in Specific Aims 1 and 2. An additional problem was the generation of BALB/c-neuT/BTLA -/-mice. Crossing F1 to BTLA -/-mice proved lethal.
KEY RESEARCH ACCOMPLISHMENTS
(1) Assessment of BTLA expression on T lymphocytes in human breast cancer by flow cytometry and immunohistochemistry. The prevalence of CD8 + BTLA + T cells in human breast cancer is less than 5%.
(2) Successful creation of wildtype and mutant HVEM constructs, and successful cloning of these constructs into retroviral and plasmid DNA vectors.
(3) Assessment of the adjuvant effect of wildtype and mutant HVEM constructs as novel molecular adjuvants in a DNA vaccine model. Wildtype HVEM does appear to be an effective molecular adjuvant.
(4) Successful establishment and validation of a clinically relevant breast cancer DNA vaccine model, representing an ideal platform for testing the wildtype and mutant HVEM constructs.
(5) Identification of an effect of BTLA-directed therapy in the treatment of graft-versus-host disease, which may have important clinical relevance in breast cancer and other diseases.
(6) Demonstration that CD8α dendritic cells, and cross-presentation, are essential for priming CD8 T cell responses following DNA vaccination.
(7) Identification of high levels of BTLA on a subset of both mouse and human dendritic cells involved in crosspresentation of antigen to CD8 T cells.
REPORTABLE OUTCOMES
The manuscript: "Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression" was published in the Journal of Experimental Medicine (JEM 2010 (JEM , 207:2552 . Please see Appendix # 6. 
CONCLUSIONS
Progress has been made towards the goal of defining the role of BTLA in breast cancer immunosurveillance.
BTLA is minimally expressed on CD8 T cells infiltrating human breast cancer; however, the surprising finding that a subset of dendritic cells expresses high levels of BTLA suggest a role for BTLA-LIGHT-HVEM interactions in CD8 T cell activation. Mechanistic studies in a model of GVHD confirm the importance of the BTLA-LIGHT-HVEM costimulatory system, and will help direct future studies. Using this protocol, three mice of a BTLA -/-x neuT cross were tested, and one was found to be positive for both BTLA-deficiency and expression of neuT (lane 2, faint band). We currently are using this mouse as a breeder in order to generate more BTLA -/-x neuT mice for future experiments. Alanine-scanning mutagenesis of HVEM. Mutated residues that reduced BTLA binding > 5-fold (red) are the points we mutated in our HVEM mutants.
PCR reactions were performed according to the manufacturer's instructions (Quick-change Lightning SiteDirected Mutagenesis kit from Stratagene). The amplification program was performed in a PTC-200 Peltier thermal cycler, and included an initial denaturation at 95°C for 2 min; 18 cycles of 95°C for 20 sec, 60°C for 10 sec and 68°C for 3 min 30 sec, and a final incubation at 68°C for 5 min. Transformation was performed immediately following PCR. Briefly, 2 µL of DpnI was aliquoted into each vial containing PCR product (50 µL), incubated at 37 °C for 5 min, then 45 µL of XL10 gold ultracompetent cells (XL10G) and 2 µL of β-ME mix were added, and the contents of the tube were swirled gently, and incubated on ice for 2 min. 2 µL of the DpnItreated DNA from each sample was then transferred to separate aliquots of XL10 G cells, mixed gently and incubated on ice for 30 minutes, followed by a 42 second-heat pulse, then incubated in tubes on ice for 2 minutes. 0.5 mL of preheated NZY+ broth was then added to each tube, and the tubes were incubated at 37°C for 1 hour with shaking at 225-250 rpm. 100 µL of each transformation reaction was then plated on an agar plate containing Amp for the plasmid vector.
The figure below demonstrates the plasmid containing the wildtype and mutant HVEM-IRES-GFP constructs:
HVEM-IRES-GFP-RV (7286 bp)
Constructs were tested by restriction enzyme digest and selected constructs were sent for sequencing to confirm mutations. After confirmation by sequencing, constructs were extracted using a maxi prep kit from Sigma Aldrich.
In order to determine if the wildtype and mutant HVEM constructs can be expressed in vitro, we transfected CHO cells with the wildtype and mutant HVEM constructs. GFP expression was assessed using a fluorescence microscope 48 hours after transfection. Subsequently, the transfected CHO cells were stained with HVEM antibody and/or BTLA tetramer followed by flow cytometry. While the wildtype and mutant HVEM constructs in retroviral vectors were prepared in the first year of the award, these key experiments to test construct expression were performed by the new postdoctoral fellow in the second year of the award.
The binding studies demonstrated that binding of BTLA is ablated in the P17A HVEM mutant, whereas binding is intact in the V36A mutant and wildtype HVEM. The Y23A mutation reduced BTLA binding by ~50% (please see below). To test the wildtype and mutant HVEM constructs in a DNA vaccine model, the constructs were cloned into the pcDNA3 vector. Two series of constructs were generated, one series with GFP (for in vitro studies) and one Once the pcDNA3 constructs were validated by restriction digest and sequencing, they were transfected into 293T cells and tested for expression in flow cytometry analyses. Please see below.
(C) Expression of wildtype and mutant HVEM in 293T cells.
(D) Expression of wildtype and mutant HVEM with GFP in 293T cells. All constructs stain positive for HVEM, but the P17A mutation completely ablates BTLA binding, and the Y23A mutation partially ablates BTLA binding.
These data show that the wildtype and mutant HVEM constructs are expressed and can be recognized by HVEM-specific antibodies. They also confirm the P17A mutation completely abrogates BTLA binding in vitro, whereas the Y23A mutation partially abrogates BTLA binding. by ELISPOT assay using splenocytes (see below).
In three independent experiments, administration of wildtype HVEM enhanced the immune response to OVA cDNA. However, unlike wildtype HVEM, the P17A mutant HVEM did not enhance vaccine efficacy.
We performed similar experiments using an electroporation device in a more clinically relevant breast cancer model (see appendix #5 for details on the model). Specifically, we combined wildtype HVEM DNA with breast cancer vaccines, such as neuT cDNA or a single chain trimer DNA vaccine targeting neuT (Kd/Ld SCT).
Groups of five BALB/c mice each were vaccinated by electroporation on days 0 and 21. Mice were vaccinated with (1) vector, (2) KdLd SCT DNA, (3) KdLd SCT DNA + wildtype HVEM DNA, (4) neu cDNA, and (5) The data show that administration of HVEM DNA reduced the immune response unlike in the OVA model.
Together these data are confusing and may require more in-depth mechanistic studies on HVEM-BTLA-LIGHT signaling.
Appendix #5: Establishment and validation of a clinically relevant breast cancer vaccine model
While waiting for sufficient numbers of BALB/c-neuT mice, we initiated DNA vaccination experiments using the BALB/c mouse breast cancer carcinoma, TUBO. TUBO is a transplantable tumor line that originates from a BALB/c-neuT mouse. TUBO expresses neuT, and DNA vaccination against neuT induces TUBO cell rejection.
We assessed the efficacy of various neuT DNA vaccines in wild type BALB/c mice challenged with TUBO. In addition to neuT cDNA, we tested two single chain trimer ( and SCT DNA vaccination protected against a lethal challenge of TUBO. The data from the SCT DNA vaccination suggest that neu-specific CD8 T cells were elicited and were capable of rejecting TUBO.
Wild type BALB/c mice (7 per group) were vaccinated on days 0, 3, and 6 by electroporation. On day 37 post immunization, mice were challenged by subcutaneous injection of TUBO (3x105/mouse). Tumor growth was measured every three days using calipers.
To further assess the peptide-specific response elicited by SCT DNA vaccination, ELISPOT assays were performed on splenocytes from vaccinated mice post vaccination.
BALB/c mice (3 per group) were vaccinated on days 0, 3, and 6 by electroporation using empty vector DNA or SCT DNA, as indicated plus adjuvant (genetic constructs encoding IL-15 and IL-15Rα). On day 11, ELISPOT assays were performed on isolated splenocytes pulsed with the respective peptides encoded by the SCT constructs. challenged with syngeneic fibrosarcomas that normally are rapidly rejected in a T cell-dependent manner [3, 4] .
Two different fibrosarcomas were rapidly rejected by wildtype mice but grew progressively in Rag2 −/− mice and 
CD8α
+ DC express very high BTLA and may activate HVEM signaling in CD8 + T cells. Dr. Murphy's laboratory discovered BTLA [6] and identified its ligand HVEM [18] . Although BTLA was initially described as a T cell co-inhibitory molecule, we have now demonstrated that signaling in the BTLA-HVEM costimulatory system is bidirectional [7] [8] [9] [10] [11] [12] , and the overall impact of BTLA expression on immune responses has not been fully elucidated. In preliminary studies we focused on targeting the BTLA-HVEM-LIGHT costimulatory system to enhance vaccine efficacy. We demonstrated that HVEM can be used as a molecular adjuvant in DNA vaccination, providing important proof-of principle that BTLA can be successfully targeted. These studies prompted us to measure BTLA expression by CD8α + DC, and we have now made the surprising finding that murine CD8α + DC express the highest levels of BTLA of any immune cell, much higher than B cells and other types of DC (Figure 4 ). This could provide CD8α + DC with the unique ability to strongly activate CD8 + T cells via HVEM. We know that HVEM is important for CD8 + T cell responses against Listeria monocytogenes [13] . In collaboration, we have now demonstrated that HVEM is required for CD8 + T cell memory following vaccinia infection (submitted), suggesting costimulation via BTLA on CD8α + DC may be required. We will further test the importance of BTLA expression by CD8α + DC in the CD8 + T cell response to vaccination. Of note, we have extended our studies to human CD141 + DC, demonstrating that this subtype also expresses BTLA at very high levels ( Figure 5 ).
This work is currently being written for publication as brief definitive report to be submitted to the Journal of Experimental Medicine. More importantly, we (Drs. Gillanders and Murphy) were recently successful in securing funds to continue this exciting research. 
Br ief Definitive Repor t
Replacement of an abnormal lymphohemato poietic system by allogeneic hematopoietic stem cell transplantation (aHSCT) from a healthy donor is an effective treatment for many dis orders of the hematopoietic system (Sykes and Nikolic, 2005; Copelan, 2006) . Induction of a mixed hematopoietic donorhost chimerism can induce longlasting tolerance to foreign tis sues without the need for lifelong immuno suppressive therapy (Kawai et al., 2008) . aHSCT therapy has been improved by better donor identification (Petersdorf et al., 2004) , more tolerable conditioning regimens (McSweeney et al., 2001) , and enhanced supportive care. However, significant treatmentrelated morbidity and mortality from chemotherapy, radiotherapy, infections, and graftversushost disease (GVHD) remain significant clinical problems. Therefore, aHSCT is commonly indicated only for treat ment of conditions where other treatment op tions are far inferior or lacking.
Costimulatory molecules of the CD28 and TNF families regulate GVHD, with inhibitory and activating receptors either decreasing or in creasing its severity (Tamada et al., 2000; Blazar et al., 2003; Xu et al., 2007) . B and T lympho cyte associated (BTLA) is an inhibitory immu noglobulin superfamily receptor, whose ligand is the TNF receptor herpesvirus entry mediator 
Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression
expressed by recipient mice might regulate GVHD in this model, we used BTLA / CB6F1 hosts as recipients of BTLA / BM and splenocytes (Fig. S1 a) . BTLA / donor cells induced similar GVHD in BTLA +/ and BTLA / hosts, which is comparable to GVHD by WT donor cells (Fig. 1 a) . Col lectively, these data suggest that BTLA does not normally regu late GVHD.
Because BTLA generates inhibitory signals and functions in autoimmunity (Watanabe et al., 2003) , malaria infection (Lepenies et al., 2007) , and intestinal inflammation (Steinberg et al., 2008) , we wondered whether harnessing the inhibitory effects of BTLA on the immune response by forced engage ment would attenuate GVHD. To test this, we compared the effects of an agonistic nondepleting antiBTLA monoclonal antibody Lepenies et al., 2007) , 6A6, administered at the time of aHSCT (Fig. 1 b) with an iso type control antibody, PIP, that recognizes bacterial GST (Gronowski et al., 1999) . Mice treated with PIP showed sim ilar progression of GVHD (Fig. 1, a and b) , with clinical scores between 3 and 4 persisting for >140 d (Fig. S1 b) . GVHD was associated with thickening of the lamina propria and muscularis, with severe inflammation and ulceration of (HVEM) and which has only been examined in a nonirradi ated model of chronic allostimulation without classical GVHD where donor cells lacking BTLA failed to persist . The role of BTLA in aHSCT using irradiated recipients, in which clinical symptoms and pathology similar to human GVHD develop, has not been examined.
RESULTS AND DISCUSSION
To determine the role of BTLA in the development of GVHD, we first examined WT and BTLA / donor mice (Watanabe et al., 2003 ) using a nonlethal parentintoirradiated F1 model of aHSCT (Stelljes et al., 2008) . In this model, GVHD results from partial MHC mismatch between H2 b haplotype donor cells and lethally irradiated H2 b/d haplotype recipients. BM and splenocytes from WT or BTLA / mice on the C57BL/6 background were transferred into lethally irradiated CB6F1 recipients (Fig. 1 a) . Transplantation of WT donor cells into CB6F1 recipients caused body weight loss of 30% and clinical scores (Cooke et al., 1996) Br ief Definitive Repor t within 30 d after aHSCT from severe GVHD (Fig. 1 e, right) . Although mice that received the antiBTLA treatment were not fully protected from GVHD, with clinical scores ranging from 1 to 3 ( Fig. 1 e, middle) and slightly more weight loss than the control group that had received T cell-depleted BM cells (BMCs [TCDBMs]) alone (Fig. 1 e, left) , 70% of recipients treated with 6A6 survived for >200 d after aHSCT.
Although the precise molecular targets of BTLA signaling are still obscure (Gavrieli and Murphy, 2006; Wu et al., 2007) , BTLA engagement by HVEM can inhibit T cell pro liferation in vitro and promote tolerance induction in vivo (Liu et al., 2009 ). Therefore, we asked if antiBTLA treatment alters donor T cell proliferation or IL2 production in vivo. CFSElabeled donor splenocytes were transferred into CB6F1 recipients that were treated with PIP, 6A6, or 6F7. Donor T cell proliferation was assessed after aHSCT and, by 3 d after aHSCT, reduced CFSE levels sug gested that proliferation had occurred (Fig. 2 e) . CD4 + T cells had reduced proliferation after treatment with 6A6 and 6F7 antibodies 3 d after aHSCT (Fig. 2 e, middle) , and the total accumulation of donor CD4 + T cells was significantly reduced compared with control (P < 0.0018 and P < 0.0083; Fig. 2 b) . In contrast, CD8 + T cell proliferation and accu mulation were not significantly affected by 6A6 treatment (P < 0.8489; Fig. 2 , a and e, left). As 6F7 treatment leads to partial depletion of cells, we also assessed the level of annexin V binding, which is an indicator of early apoptosis. Mice treated with 6F7, but not PIP or 6A6, showed increased bind ing of annexin V on CD4 + and CD8 + T cells 7 d after aHSCT, which was not observed on day 3 (Fig. S1 g) .
Although accumulation of CD4 + T cells was lower in 6A6 treated than in PIPtreated mice, the production of IL2 7 d after aHSCT was not statistically different (Fig. S2, a and b) . A small but significant reduction in IFN and IL4, but not IL17, production was observed in 6A6treated mice com pared with controls (Fig. S2, a and b) . In summary, 6A6 ad ministered at the time of aHSCT reduced the proliferation and accumulation of donorderived CD4 + Foxp3  effector T cells (T eff cells) without inducing anergy, inhibiting IL2 production or causing major alterations in cytokines.
These effects were suggestive of the actions of CD4 + Foxp3 + regulatory T cells (T reg cells) expressing the tran scription factor forkhead box P3 (Foxp3; Hori et al., 2003) . T reg cells have recently been reported to play a significant role in regulating GVHD (Taylor et al., 2002; Edinger et al., 2003b) , and there are ongoing clinical trials aimed directly at the use of T reg cells as an intervention in human GVHD (NCI clinical trial NCT00725062).
To determine whether 6A6 treatment influences T reg cells, we measured the accumulation and proliferation of donorderived T eff cells after aHSCT (Fig. 2, c and e, right) . In PIPtreated recipients that developed GVHD, significantly fewer T reg cell were detected 7 d (P < 0.0393) after aHSCT when compared with recipients that received either anti BTLA treatment 6A6 or 6F7 (Fig. 2 c) . Therefore, anti BTLA treatment inhibits the proliferation of T eff cells yet the colon (Stelljes et al., 2008;  Fig. S1 c, bottom) . In contrast, a single treatment of 10 µg/g body weight of 6A6, given at the time of aHSCT, prevented GVHD completely, with weight loss and GVHD similar to the syngeneic control group (Fig. 1 b) for 140 d after aHSCT (Fig. S1 b) . Furthermore, 6A6treated mice had no histological evidence of GVHD in the colon (Fig. S1 c, top) . Thus, a single administration of antiBTLA antibody eliminates weight loss, histological changes, and clinical signs of GVHD.
We next asked if 6A6 acted by simply depleting donor cells that express BTLA. As a positive control, we included a de pleting murine antiBTLA antibody, 6F7 Truong et al., 2009) . CFSElabeled donor cells were trans ferred into WT recipients that also received PIP, 6A6, or 6F7 antibody. 2 d after transfer, we found similar numbers of CFSE + cells in mice that received either PIP or 6A6 antibody (Fig. S1 d, left) and no significant differences between numbers of CD19 + , CD4 + , or CD8 + lymphocytes (Fig. S1 d, right) . Treatment with 6F7 caused a significant depletion of CFSE + lymphocytes, particularly from the CD19 + cell population (Fig. S1 d) . Furthermore, surfacebound 6A6 was detectable on live donorderived cells in vivo up to 7 d after transfer (Fig. S1 e) . In addition, 6A6 treatment was unable to prevent GVHD caused when BTLA / donors were used as a source of BM for aHSCT (Fig. S1 f) . Thus, 6A6 does not deplete lympho cytes Lepenies et al., 2007) but requires the expression of BTLA on donor cells to prevent GVHD.
Next, we asked if 6A6 could reverse established GVHD. We compared immediate with delayed administration of 6A6 (Fig. 1 c) . Again, immediate 6A6 administration pre vented GVHD. In contrast, there was no statistical difference in weight loss or clinical scores between mice that received 6A6 14 d after aHSCT and with mice that received PIP (Fig. 1 c) .
6A6 binds to a region of BTLA that is involved in inter actions with HVEM . Thus, 6A6 might prevent GVHD by preventing HVEM and BTLA interac tions, thus blocking costimulatory signaling to donor cells (Xu et al., 2007) . Although our data indicated that host BTLA is not involved (Fig. S1 a) , we wished to test this pos sibility independently. Transfer of HVEM / donor cells caused induction of GVHD when administered with PIP ( Fig. 1 d) . The severity of GVHD caused by HVEM / donor cells was somewhat less than that caused by WT donor cells (Fig. 1 b) , consistent with a study which found that HVEM and LIGHT are costimulatory in promoting GVHD (Xu et al., 2007) . However, 6A6 also prevented GVHD caused by HVEM / donor cells (Fig. 1 d) . These results in dicate that 6A6 prevents GVHD in a manner that is indepen dent of HVEM, suggesting it acts directly through BTLA.
Because the parentintoirradiated F1 model of aHSCT does not result in lethal GVHD, we wished to test the potency of the antiBTLA treatment in a model of complete MHC mismatch (H2 b into H2 d ) that results in lethal GVHD in un treated mice (Lu et al., 2001; Edinger et al., 2003b) . Control mice developed severe GVHD with pronounced weight loss and clinical scores of >6 (Fig. 1 e, left and middle) and died on November 12, 2012 jem.rupress.org Downloaded from mice as donors, using purified GFPnegative cells from Foxp3 gfp mice to remove preexisting T reg cells from the donor population. In this mixed aHSCT setting, 6A6 treatment similarly de creased the accumulation of T eff cells in both populations, but T reg cells expanded only from preexisting T reg cells (Fig. 2, f and g; and Fig. S2 , e and f). Therefore, the donor T reg/T eff cell ratio increased only among the WT donor T cells and not in the Foxp3 gfp donor T cells, as assessed by intracellular staining for endogenous Foxp3 (Fig. 2 f and Fig. S2 g ). In addition, donor derived CD4 + T cells, which were originally isolated from B6.Foxp3 gfp mice as negative for GFP expression, remained negative for Foxp3 as assessed by the Foxp3GFP reporter (Fig. S2 e, right) .
To further characterize the conditions necessary for the expansion of T reg cells, we evaluated what effects anti BTLA treatment had on T reg cells in the steady state and whether the presence of alloantigen or HVEM on host tissue is required. When unmanipulated B6.Foxp3 gfp mice received 6A6, the frequency of T eff cells, T reg cells, or the resulting ratio did not change (Fig. S3, a-d) . Similarly, although syn geneic aHSCT of CB6F1 resulted in a small decrease of T eff cells 7 d after transplant, no major accumulation of T reg cells and no increased T reg/T eff cell ratio was observed (Fig. S3 , e-h). When HVEM / donors and MHCmismatched HVEM / recipients were used, the ratio of T reg/T eff cells increased by inhibiting the accumulation of T eff cells allows the accumulation of T reg cells, resulting in an in creased T reg/T eff cell ratio (P > 0.0028; Fig. 2 d) . This re sult is in agreement with the demonstration that T reg cells maintain low levels of BTLA after activation, in contrast to conventional T cells which upregulate BTLA expression upon activation (Fig. S2 c; Hurchla et al., 2005) . Thus, 6A6 treatment increases the numbers and the frequency of donor derived T reg cells after aHSCT.
6A6 treatment could increase T reg cell frequency either by inducing Foxp3 expression in naive donor CD4 + T cells (Chen et al., 2003) or by causing in vivo expansion of preexisting donor T reg cells relative to T eff cells. To distinguish these alter natives, we used B6.Foxp3 gfp reporter mice (Fontenot et al., 2005) . We performed mixed aHSCT with WT and Foxp3 gfp on November 12, 2012 jem.rupress.org
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Published November 15, 2010 Br ief Definitive Repor t CD4 + BTLA / population did not change in the presence of 6A6 (7.9 ± 2 vs. 7.3 ± 2%; Fig. 3, a and c) , whereas the T reg cell frequency within the CD4 + WT population increased more than threefold in the presence of 6A6 (48 ± 10 vs. 14.4 ± 5.5%; Fig. 3, a and b) .
Importantly, 6A6 treatment decreased T eff cell numbers more than fivefold from 2.6 × 10 5 ± 4.6 × 10 4 cells in the control group to 3.9 × 10 4 ± 1.4 × 10 4 (P < 0.0001; Fig. 3 d) , indicating that WTBTLA +/+ T eff cells are the main target of the antiBTLA treatment. WT and BTLA / T reg cells (Fig. S3 , i-l) as observed before (Fig. 2, d and g ). Collec tively, these results suggest that 6A6 has no effect in the steady state, does not involve HVEM, and requires allostimulation to increase the T reg/T eff cell ratio.
Because BTLA is expressed on both T eff and T reg cells, we tested whether the increased T reg/T eff cell ratio was the result of a decrease in T eff cell expansion, an increased pro liferation of T reg cells, or both by performing a mixed aHSCT using congenically marked WT BTLA +/+ and BTLA / donors. In this setting, the frequency of T reg cell within the shown as mean ± SD from two independent experiments. P-values of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.
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T reg/BTLA / T eff cell ratio even decreased (Fig. 3 g and  Fig. S4 i) , suggesting that low expression levels of BTLA on T reg cells inhibits their expansion when proliferation of BTLA / T eff cells is not restricted.
To ask whether the inhibition of T eff cells had an effect on GVHD in the absence of T reg cells, we used C57BL/6 Foxp3 DTR mice as donors in the lethal model of GVHD. Pre treatment with diphtheria toxin reduced T reg cells by >95% in Foxp3 DTR donors. 90% of control animals died within 14 d of aHSCT, irrespective of whether or not the BM graft con tained T reg cells (Fig. 3 h) . All mice that were treated with the 6A6 antibody survived beyond day 70 (Fig. 3 h) . Mice that re ceived a graft with T reg cells and 6A6 eventually recovered to 90% of their starting weight (Fig. 3 i) and developed do not expand significantly in the presence of BTLA / T eff cells (Fig. 3 e) , confirming our observation that T reg cells expand only when T eff cells express BTLA and are inhibited by 6A6. To exclude any indirect effects on host tissues, we cotransferred purified populations of WT T reg cells together with WT or BTLA / T eff cells into BALB/c recipients, which express an allele of BTLA not recognized by 6A6 (Fig. 3 , f and g; and Fig. S4 ; Hurchla et al., 2005) . The WT T reg/ WT T eff cell ratio increased after 6A6 treatement (P < 0.0004; Fig. 3 f) as observed before (Fig. 2 g and Fig. 3 b) . In contrast, when BTLA / T eff cells were present the WT T reg/ BTLA / T eff cell ratio did not increase (Fig. 3 g) , indicat ing that the expansion of T reg cells is caused by 6A6 reduc ing the expansion of T eff cells. In this setting, the WT (c) Survival data of mice from a and from mice that received TCD-BM alone without tumor for comparison. Shown are cumulative data from two independent experiments. (d) CB6F1 BMC and splenocytes from syngeneic (green line; n = 10) or C57BL/6 donors and antibodies PIP (red line; n = 10) or 6A6 (blue line; n = 10) were infected with MCMV 4 wk after aHSCT and were monitored for survival. PIP-treated uninfected mice (orange line, n = 10) served as controls. Shown are cumulative data from two independent experiments. Data are shown as mean ± SD from two independent experiments. P-values of >0.05 are considered not significant (n.s). **, 0.001 < P < 0.01; ***, P < 0.001.
Published November 15, 2010 Br ief Definitive Repor t cells and allowing the relative expansion of naturally occur ring T reg cells. Once established, this new balance of T eff cells is sufficient to prevent GVHD permanently while allowing for intact responses to viral and bacterial pathogens, as well as GVT effects. Thus, BTLA may represent a novel therapeutic target in prevention of human GVHD. Increas ing the safety of aHSCT could potentially allow its appli cation more widely as a tolerogenic therapy in treatment of autoimmune disorders or solid organ transplantation, for which it is currently performed only experimentally (Sykes and Nikolic, 2005; Kawai et al., 2008) .
MATERIALS AND METHODS
Mice and BM transplantation. B6.SJLPtprca Pep3b/BoyJ (B6.SJL), C57BL/6, and C57BL/6 × BALB/c F1 (CB6F1) mice were obtained from The Jackson Laboratory or bred in our facility. BTLA / (Watanabe et al., 2003) , Hvem / (Wang et al., 2005) , Foxp3 gfp (Fontenot et al., 2005) , and Foxp3 DTR (Kim et al., 2007) Cell transplantation and assessment of GVHD. Mice received trans plants according to a standard protocol as previously described (Stelljes et al., 2008) . In brief, BMCs were harvested by flushing tibia and femurs of donor mice. For the nonlethal parentintoF1 model of GVHD, CB6F1 (H2 b/d ) recipients were lethally irradiated with 9 Gy total body irradiation using a 137 Cs source at a dose rate of 70 cGy/min and reconstituted with 2 × 10 7 BMCs and 10 7 splenocytes from syngeneic (H2 b/d ) or parental C57BL/6 donors (H2 b ). For the lethal model of GVHD, BALB/c (H2 d ) recipients were lethally irradiated with 8 Gy total body irradiation using a 137 Cs source at a dose rate of 70 cGy/min and reconstituted with 2 × 10 7 TCDBM alone or an additional 10 7 splenocytes from allogeneic C57BL/6 donors (H2 b ). To obtain TCDBM, cells were depleted of CD4 + and CD8 + cells by mag netic depletion (Miltenyi Biotec) according to the manufacturer's recom mendation. In experiments where a T reg cell-depleted graft from Foxp3 DTR donors was used, recipients received an intraperitoneal injection of 20 µg diphtheria toxin on the day of BMT. GVHD was monitored by calculating the loss in total body weight. Body weights were measured before transplan tation and three times a week after transplantation. Clinical GVHD intensity was scored by assessing weight loss, posture, activity, fur texture, and skin integrity (Cooke et al., 1996) . Histopathologic analyses of the bowel were performed on hematoxylin and eosin-stained tissue.
Administration of antibody.
In some experiments, mice received at the time of aHSCT, unless otherwise noted, a single intraperitoneal injection of 10-20 µg/g body weight of antiBTLA antibodies 6A6 and 6F7, whose proper ties we have previously published in detail . In brief, the IgG hamster monoclonal antibody 6A6 is specific for the C57BL/6 allele of BTLA and does not deplete BTLAexpressing cells in vivo Lepenies et al., 2007) . The IgG1 mouse monoclonal antiBTLA antibody 6F7 recognizes all known alleles of BTLA and has been shown to deplete BTLAexpressing cells in vivo. The IgG1 hamster monoclonal anti GST antibody PIP (Gronowski et al., 1999) was used as an isotype control.
Cell purification and depletion. To obtain purified populations of CD4 + Foxp3 gfp negative cells or CD4 + Foxp3 gfp positive cells in the indicated ex periments, Foxp3 gfp splenocytes were stained with CD4 + and the desired population was purified by cell sorting on the MoFlo cytometer (Dako).
lowgrade GVHD with scores ranging from 1 to 3, as seen be fore (Fig. 1 e) . Mice that received a T reg cell-depleted graft and 6A6, however, recovered only 70-80% of their starting weight and had more severe GVHD scores ranging from 3 to 5 (Fig. 3 j) . These data highlight that forced inhibition of T eff cells through BTLA (Fig. 3 d) is sufficient to prevent lethality. Nonetheless, the relative expansion of T reg cells (Fig. 3, b and f) bears biological significance, as they are required to protect the host from clinical GVHD (Fig. 3, i and j) .
Because engagement of BTLA by 6A6 inhibited T eff cell proliferation, we wondered whether this treatment allowed for antigenspecific responses to tumors and pathogens. First, we examined whether graftversustumor (GVT) activity was maintained after 6A6 treatment (Fig. 4, a-c) . We used a model of minimal residual disease after aHSCT that utilizes biolumi nescence imaging (BLI) of luciferaseexpressing A20Luc leu kemia cells (H2 d ) in vivo (Edinger et al., 2003a) . In this model, GVT activity requires cytolytic activity of T cells to control the tumor (Edinger et al., 2003b) . Transplantation of A20Luc leu kemia cells with TCDBM alone resulted in progressive tumor growth (Fig. 4, a and b) . In mice that had received a T cellcontaining graft with or without the 6A6 antibody, however, tumor was never detectable by BLI, suggesting that GVT ef fects were intact. Although all control mice died before day 45 of severe GVHD, 90% of 6A6treated mice survived beyond day 90 (Fig. 4 c) . To exclude any antibodymediated anti tumor effects, we confirmed that the 6A6 antibody does not bind to A20 cells, which was expected because of their BALB/c origin (Fig. S2 d) . To document initial tumor engraftment, we quantified the total tumor number A20GFP cells in the BM by flow cytometry 7 d after aHSCT (Fig. S3 m) .
We next examined immune responses to murine CMV (MCMV; Nguyen et al., 2008) 4 wk after aHSCT. All ani mals that had undergone syngeneic aHSCT survived for >60 d after infection (Fig. 4 d) . Of the mice in the allogeneic group that had received the PIP antibody, 70% died within 10 d of infection compared with 20% of the 6A6treated mice. Thus, although 6A6 treatment prevents GVHD, it allows for resis tance to MCMV, unlike PIPtreated control recipients.
To test the immune response against bacterial infection, animals were infected with the intracellular bacterium Listeria monocytogenes. 3 d after infection, animals that had received the PIP antibody had either higher (P = 0.0005 for liver and P = 0.1816 for spleen) or lower L. monocytogenes organ bur dens (P = 0.0227 for liver and P = 0.0059 for spleen; Fig. S3 , n-p), as has been described previously (Miura et al., 2000) . In contrast, antiBTLA-treated mice controlled infection similarly to both control groups, indicating an intact innate immune response (Fig. S3, n-p) . These preliminary results suggest that 6A6treated mice were similarly resistant to L. monocytogenes infection to unmanipulated mice.
In summary, this study demonstrates that the antiBTLA antibody 6A6 administered at the time of aHSCT prevents GVHD without the need for additional immunosuppressive therapy. The mechanism of action is through direct engage ment of BTLA on donor T cells, selectively inhibiting T eff on November 12, 2012 jem.rupress.org Downloaded from (SigmaAldrich) and 5 µg/ml LPS and spun at 930 rcf for 1 h before being cul tured at 37°C for 24 h. 72 h after infection, cells were sorted for high GFP ex pression on a FACSAria II (BD) and stable GFP expression of >95% was confirmed several times by flow cytometry at later time points.
Models of infectious disease. For MCMV infection, mice were infected with Smith strain MCMV 4 wk after aHSCT. Virus preparation and admin istration was performed as described previously (Krug et al., 2004) . In brief, a salivary gland stock of MCMV was prepared from BALB/c mice, with a titer of 6.75 × 10 6 PFU/ml. Mice were infected intraperitoneally with a low dose of virus (10 4 PFU/mouse) and then monitored for survival. For L. monocytogenes infection, mice were infected intravenously with 2.5 × 10 4 L. monocytogenes (strain EGD; gift from E.R. Unanue, Washington Univer sity School of Medicine, St. Louis, MO) 3 mo after aHSCT. To determine organ L. monocytogenes burden at day 3 after infection, spleens and livers were homogenized in PBS plus 0.05% Triton X100. Serial dilutions of homoge nate were plated on brain heart infusion agar, and bacterial CFUs were as sessed after overnight growth at 37°C. Small portions of spleen and liver were also fixed in 10% formalin and stained with hematoxylin and eosin.
Statistical analysis. A Student's unpaired twotailed t test with a 95% con fidence interval was used for statistical analyses of body weight data, clinical scores, and cell numbers. For analyses of survival data the logrank test was used. A MannWhitney unpaired twotailed Student's t test with a 95% confidence interval was used for statistical analyses of bioluminescence data in Fig. 4 . Statistical analyses were done using Prism 4 (GraphPad Software, Inc.). FACS data are expressed as means ± SEM. All other data are presented as means ± SD. All experiments have been repeated at least once with three to five mice per group, unless stated otherwise.
Online supplemental material. Fig. S1 demonstrates that BTLA expres sion by recipient tissue does not promote GVHD and 6A6 antibody does not deplete lymphocytes. Fig. S2 shows that 6A6 treatment does not lead to donor T eff cell anergy and expands preexisting T reg cells. Fig. S3 shows that 6A6 inhibition of T eff cells and expansion of T reg cells requires allostimu lation but not HVEM expression by donor or host. Fig. S4 shows that 6A6 alters the T reg cell/effector CD4 + T cell ratio by directly inhibiting BTLA expressing T cells. Online supplemental material is available at http://www .jem.org/cgi/content/full/jem.20102017/DC1.
Purification of C57BL/6 CD4 + and BTLA / CD4 + cells was obtained from splenocytes that were depleted of CD8 + and B220 + cells by magnetic depletion (Miltenyi Biotech) according to the manufacturer's recommenda tion. Foxp3 DTR mice received intraperitoneal injections for 2 d of 20 µg diphtheria toxin per day before harvesting BM and splenocytes for aHSCT.
CFSE labeling and flow cytometry. Cells were labeled with CFSE (SigmaAldrich) by being incubated for 8 min at 25°C with 1 µM CFSE at a density of 40 × 10 6 cells per ml in PBS. Labeling was quenched by incubation of cells for 1 min with an equal volume of FCS and cells were washed twice with media containing 10% (vol/vol) FCS. 50 × 10 6 total cells per mouse were injected intravenously. Single cell suspensions from spleens were ana lyzed by flow cytometry using the following antibodies for detection: PerCPCy5.5, v450 (RM45) and PE (GK1.5), CD8v450 (53-6.7), anti-Armenian and Syrian hamster IgG cock tailPE, CD19APC (1D3), and annexin V-PE (BD); and CD45.1PECy7 and APC (A20), CD45.2APCeFluor780 (104), CD8APC Alexa Fluor 750 (53-6.7), CD4APC Alexa Fluor 750 (RM45), BTLAbio (6F7), and SA v450 (eBioscience). Intracellular Foxp3 was detected using the Mouse Regu latory T cell staining kit (eBioscience) with Foxp3PE or APC (FJK16s). For intracellular cytokine staining, splenocytes were first restimulated with PMA/ ionomycin for 4 h and were stained with antibodies to surface markers, fol lowed by fixation with 2% formaldehyde for 15 min at room temperature. Cells were then washed once in 0.05% saponin and stained with anticytokine antibodies (antiIL17 FITC, IL2 PE, IFN PECy7, and IL4 APC) in 0.5% saponin. All flow cytometry data were collected on a FACSCanto II (BD) and were analyzed with FlowJo software (Tree Star, Inc.).
Tumor model and assessment of GVT effects. As a tumor challenge, 2 × 10 4 A20Luc or A20GFP where administered intravenously together with the donor graft as indicated. Imaging was done as previously described (Rehemtulla et al., 2000; Edinger et al., 2003a) . In brief, dLuciferin (Bio synth AG) was reconstituted in 0.9% sodium chloride (Baxter) to a concen tration of 15 mg/ml, filtered (0.2 µm), and frozen at 80°C until use. Mice were given intraperitoneal injections at a dose of 150 mg/kg and allowed to remain active in the cage for 5 min to allow circulation of luciferin. Using the Xenogen IVIS 200 system (Caliper Life Sciences) with attached anesthesia chamber, the animals were then anesthetized with 2% isoflurane for 5 min and subsequently transferred to the imaging chamber where they continued to receive a regulated flow of isoflurane through the manifold's nose cones. The Living Image software program (Caliper Life Sciences) was used to obtain and analyze data. For all experiments, a 60s exposure time was used. To detect A20GFP in the BM, single cell suspensions from both femurs were analyzed by flow cytometry using the antibody CD19APC (1D3; BD). Cells that ex pressed high levels of CD19 and GFP were considered to be A20GFP cells.
Cell lines. The BALB/c B cell lymphoma cell line A20 was obtained from the American Type Culture Collection. To generate luciferaseexpressing A20 cells (A20Luc), a 1995bp HindIII-BamHI fragment from pGL4.23[luc2/minP] vector (Promega) containing a minimal promoter, a Luc2 coding sequence, and a SV40 late poly(A) signal was cloned into the HindIII and BamHI sites of the pcDNA3.1 + mammalian expression vector (Invitrogen) to generate pcDNA3.1 + Luc2. For stable transfections, 10 × 10 6 A20 cells/ml in complete IMDM supplemented with 10% fetal calf serum and with 30 µg/ml PvuI linearized pcDNA3.1 + Luc2 were electroporated at room temperature in 0.4ml aliquots in 0.4cm cuvettes in a Gene Pulser (BioRad Laboratories) at 240 V and 960 mF. After electroporation, cells were cultured for 24 h in IMDM supplemented with 10% fetal calf serum and then selected in the pres ence of 800 µg/ml geneticin. To generate GFPexpressing A20 cells, a retro viral reporter vector (Ranganath et al., 1998) was used that contains the coding sequence of herpes simplex virus 1 thymidine kinase, followed by an internal ribosomal entry site and GFP (HSV1TKIRESGFPRV). The retroviral vector was packaged in Phoenix A cells. Before infection, the A20 cell line was stimulated with 5 µg/ml LPS (SigmaAldrich) for 24 h. For infection, cells were cultured in retroviral supernatant supplemented with 8 µg/ml polybrene on November 12, 2012 jem.rupress.org Downloaded from binding groove through a disulfide bond between the linker and heavy chain ( Fig. 2A) (7) (8) (9) . Moreover, SCTs are recognized as intact molecules, because the D227K mutation in the α3 domain of the OVA/K b SCT abrogates CD8 interaction (14) and induces diminished K b -specific CD8 + T-cell responses when used in a DNA vaccine (Fig. S2A) . Similarly, a chimeric A2D b /West Nile virus SCT showed increased responses in HHD II mice transgenic for the same chimeric A2D b class I MHC molecules (15) ( Fig. S2B) . Together, these data show that SCT constructs are recognized as intact complexes. Previous studies did not exclude the possibility that the peptide in an SCT complex could additionally be cross-presented. We, therefore, generated an SCT, p5Y/K b SCT ( Fig. 2A) , that contains an altered OVA peptide ligand SIINYEKL, which binds to K b with a 1,000-fold lower affinity compared with the WT peptide were collected before and after vaccination. OVA-specific total IgG, IgG 1 , and IgG 2a were measured by ELISA, and the levels were equivalent between WT and Batf3 −/− mice. *P < 0.01; ns, not significant; SFC, spot forming cells. SIINFEKL (Fig. S3) (16) . To test whether this altered peptide from the SCT could be cross-presented, we immunized mice with DNA vaccines with the keratinocyte-specific K14 promoter (17) driving expression of cDNA or SCT constructs corresponding to either WT OVA or the mutant SIINYEKL sequence (Fig. 2B) . Immunization using WT OVA cDNA induced strong CD8 + T-cell responses, but immunization with a cDNA encoding OVA with the altered SIINYEKL sequence failed to induce CD8 + T-cell responses. This result indicates that the altered epitope binds too weakly to allow presentation by endogenous H-2K b MHC molecules via conventional processing pathways (16) . Immunization with the SCT harboring either the WT SIINFEKL or the altered epitope SIINYEKL presented by K b induced equally strong CD8 + T-cell responses. These results show that SCTs are recognized as an intact complex and can prime T-cell responses to peptide epitopes that cannot be conventionally cross-presented because of low affinity for MHC.
Cross-Dressed DCs Prime CD8 + T Cells in Vivo and in Vitro. Efficient CD8 + T-cell priming after epicutaneous DNA immunization using the K14 promoter (17) suggests that SCTs are produced in keratinocytes but transferred to DCs. Alternately, T-cell priming could have resulted from direct recognition of SCTs expressed by keratinocytes and so could be independent of DCs. To test these hypotheses, we immunized WT and Batf3 −/− mice with SCT DNA vaccines driven by the K14 promoter expressing the SII-NYEKL epitope presented by K b . This vaccination induced strong CD8 + T-cell responses in WT mice, but CD8 + T-cell responses were reduced to background in Batf3 −/− mice (Fig. 3A) . Thus, CD8 + T-cell priming by vaccination with DNA encoding an SCT requires the participation of CD8α + /CD103 + DCs. Potentially, these DCs were directly transfected by the DNA vaccine to generate SCT complexes rather than obtaining these complexes from keratinocytes. To test this possibility, we stably expressed the p5Y/K b SCT into mouse embryonic fibroblasts lacking endogenous K b , D b , and β2m (3KO MEFs). We adoptively transferred carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled OT-1 T cells into C57BL/6 mice, and then vaccinated mice 24 h later with necrotic 3KO p5Y/K b SCT MEFs or 3KO MEF parental control cells. After 90 h, draining lymph nodes were harvested and OT-1 proliferation was analyzed by flow cytometry. Vaccination of WT mice with 3KO p5Y/K b SCT MEFs, but not control parental cells, induced strong proliferation of OT-1 T cells in vivo (Fig. 3B and Fig. S4A ). However, this proliferation is absent in Batf3 −/− mice (Fig. 3B) , indicating that the in vivo proliferation was not attributable to direct recognition of the p5Y/K b SCT on MEFs but required presentation of these complexes by Batf3-dependent CD8α + /CD103 + DCs. Vaccination with live 3KO p5Y/K b SCT MEFs can also induce an endogenous K b /SIINFEKL-specific immune response as measured by IFN-γ ELISPOT (Fig. S4B) . This result suggests that the p5Y/K b SCT expressed on MEFs was transferred to CD8α + / CD103 + DCs, which induced proliferation of CD8 + T cells. To observe such transfer directly, 3KO p5Y/ K b SCT MEFs were subjected to several freeze-thaw cycles to induce necrosis, cultured with DC2.4 DCs, and analyzed by FACS using the OVA/K b -specific monoclonal antibody 25-D1.16 (Fig. S5A) . A detectable increase in 25-D1.16 staining was observed on DC2.4 cells cultured with 3KO p5Y/ K b SCT MEFs compared with DC2.4 cultured with control 3KO MEFs. Further, OT-1 T-cell proliferation was observed only when 3KO p5Y/K b SCT MEFs and DC2.4 cells were present (Fig. S5A ). In addition, we performed studies in vitro using the epitope-specific antibody 25.D1.16 and confocal microscopy. In these studies, we are able to demonstrate cross-dressing of intact p5Y/K b SCT complexes from 3KO p5Y/K b SCT MEFs to C57BL/B6 and transporter associated with antigen processing (TAP) −/− DCs (Fig. S5B ). These results support the interpretation that p5Y/K b SCT complexes are transferred from 3KO MEFs to DCs to activate OT-1 T cells.
Cross-Dressed DCs Activate both Naïve and Memory CD8 + T Cells.
Wakim and Bevan (4) reported that in a vesicular stomatitis virus (VSV) infection model, cross-dressed DCs activate memory, but not naïve, CD8 + T cells, whereas we find that with DNA and cellular vaccines, cross-dressed DCs efficiently activate naïve CD8 + T cells. To examine memory CD8 + T cells, we transferred in vitro-activated OT-1 cells into C57BL/6 mice and recovered memory phenotype cells after 30 d by negative selection (Fig. S6  A and B) . Memory and naïve OT-1 cells were labeled with CFSE and transferred into WT and Batf3 −/− mice, which were challenged after 24 h with necrotic 3KO p5Y/ K b SCT MEFs. Lymph nodes and spleens were harvested 90 h later, and OT-1 proliferation was examined by FACS. Vaccination with 3KO p5Y/ K b SCT MEFs induced proliferation of both naïve and memory OT-1 cells in WT mice but not in Batf3 −/− mice ( Fig. S6 C and  D) . This result suggests that at least with cell-based immunization, cross-dressed DCs are capable of inducing proliferation in both naïve and memory CD8 + T cells. Cross-Dressing Is a Robust Antigen Presentation Pathway in Vivo. To define the relative contribution of cross-presentation vs. crossdressing in the response to vaccination, we generated C57BL/ 6→TAP −/− bone marrow (BM) chimeras. In these chimeras, vaccination with the K14-OVA DNA vaccine cannot generate OVA/K b complexes from TAP −/− keratinocytes, eliminating cross-dressing but allowing cross-presentation of OVA protein by donor DCs as a route to T-cell activation. After adoptive transfer of CFSE-labeled OT-1 cells, BM chimeras were vaccinated with either a K14-OVA DNA vaccine or a K14-p5Y/ K b SCT DNA vaccine (Fig. 4A and Fig. S7 ). Both DNA vaccines induced robust proliferation of OT-1 cells in BM chimeras (Fig.  4 B and C) , suggesting that CD8 + T-cell priming occurs by both cross-dressing and by cross-presentation in this model system.
Discussion
The studies reported here provide important insights into the importance of cross-dressing as a pathway for activation of CTLs. Using engineered SCT vaccines and Batf3-deficient mice, we demonstrate that cross-dressing is a robust pathway of crosspresentation, with the ability to prime both naïve and memory CTLs. Not only do these studies have important implications for the rational design of DNA and cellular vaccines, but they also have broader implications for understanding other immune responses generally considered to be dependent on cross-priming, such as viral infection and malignancy.
Our findings differ with Wakim and Bevan (4) In addition, we have separately compared cross-presentation and cross-dressing in priming CD8 + T-cell responses. After reconstitution of TAP −/− mice with C57BL/6 BM, we compared two DNA vaccination strategies using the same keratinocytespecific promoter and model antigen. Both cross-presentation and cross-dressing pathways were able to induce similarly robust priming of CD8 + T-cell responses, suggesting that cross-dressing 
